- Stocks
- Pharma & Healthcare
- Krishna Institute of Medical Sciences
Krishna Institute of Medical Sciences share price
NSE: KIMSPharma & HealthcareMedical Care Facilities
Krishna Institute of Medical Sciences at a glance
Krishna Institute of Medical Sciences (NSE: KIMS) closed at ₹671.30 on 22 Oct 2026, up 0.04% on the day. With a market capitalisation of ₹28,195 Cr, it ranks 286th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.
At its last close the stock traded at 111.9× trailing earnings, against a return on equity of 18.0% in FY25. Over the past year the share price has fallen 5.5%. Its 52-week range is ₹575.80 (27 Jan 2026) to ₹858.00 (6 Jul 2026); the last close is 21.8% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹1,180 Cr (+35.3% year on year) and net profit ₹36 Cr (−57.2%), on a consolidated basis. Promoters held 32.50% of the company as of 30 Jun 2026; 10.26% of promoter shares were pledged.
Key numbers
- Market cap
- ₹28,195 CrRank 286 on NSE
- P/E (trailing)
- 111.9×
- Price to book
- 11.96×FY25
- EPS (TTM)
- ₹5.10to Q1 FY27
- ROE
- 18.0%FY25
- ROCE
- 13.0%FY25
- Debt to equity
- 0.89FY25
- Net profit margin
- 13.3%FY25
- Book value / share
- ₹53.45FY25
- 52-week high
- ₹858.006 Jul 2026
- 52-week low
- ₹575.8027 Jan 2026
- 1-year return
- −5.5%
- RSI (14-day)
- 28
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +0.04% | −2.9% | −15.0% | −14.8% | −5.5% |
Krishna Institute of Medical Sciences quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹777 Cr | ₹772 Cr | ₹797 Cr | ₹872 Cr | ₹961 Cr | ₹998 Cr | ₹1,075 Cr | ₹1,180 Cr |
| Revenue YoY | +19.1% | +27.5% | +25.7% | +26.6% | +23.6% | +29.2% | +34.8% | +35.3% |
| Net profit | ₹121 Cr | ₹93 Cr | ₹106 Cr | ₹85 Cr | ₹72 Cr | ₹52 Cr | ₹31 Cr | ₹36 Cr |
| Net profit YoY | +19.2% | +20.6% | +48.1% | −10.7% | −40.3% | −43.9% | −71.3% | −57.2% |
| Net margin | 15.5% | 12.0% | 13.3% | 9.8% | 7.5% | 5.2% | 2.8% | 3.1% |
| EPS | ₹2.68 | ₹2.22 | ₹2.54 | ₹1.96 | ₹1.67 | ₹1.33 | ₹1.06 | ₹1.04 |
Krishna Institute of Medical Sciences financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹1,123 Cr | ₹1,330 Cr | ₹1,651 Cr | ₹2,198 Cr | ₹2,498 Cr | ₹3,035 Cr |
| Operating profit | ₹141 Cr | ₹279 Cr | ₹447 Cr | ₹470 Cr | ₹460 Cr | ₹547 Cr |
| Net profit | ₹115 Cr | ₹205 Cr | ₹334 Cr | ₹366 Cr | ₹336 Cr | ₹404 Cr |
| EPS (₹) | ₹16.00 | ₹27.00 | ₹42.00 | ₹42.00 | ₹39.00 | ₹10.00 |
| Cash from operations | ₹202 Cr | ₹356 Cr | ₹324 Cr | ₹432 Cr | ₹521 Cr | ₹582 Cr |
| Total debt | ₹314 Cr | ₹228 Cr | ₹138 Cr | ₹497 Cr | ₹928 Cr | ₹1,654 Cr |
| Shareholders' equity | ₹598 Cr | ₹864 Cr | ₹1,387 Cr | ₹1,670 Cr | ₹1,828 Cr | ₹2,138 Cr |
Krishna Institute of Medical Sciences shareholding pattern
| Holder | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 19 Jun 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 34.11% | 34.11% | 34.11% | 34.11% | 32.50% | 32.50% |
| Foreign institutions | 15.54% | 15.03% | 14.33% | 14.57% | 14.44% | 14.74% |
| Domestic institutions | 31.66% | 32.12% | 32.71% | 32.50% | 34.59% | 34.43% |
| Non-institutions | 18.69% | 18.74% | 18.85% | 18.82% | 18.47% | 18.33% |
| Promoter shares pledged | — | — | 3.66% | 10.26% | 10.26% | 10.26% |
Krishna Institute of Medical Sciences vs peers
The listed Pharma & Healthcare companies nearest to Krishna Institute of Medical Sciences by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| MEDANTAGlobal Health | ₹1,215.10 | −1.65% | −10.1% | ₹32,671 Cr | 58.9 | — |
| LALPATHLABDr. Lal Path Labs | ₹1,838.50 | +0.46% | +16.3% | ₹30,820 Cr | 58 | — |
| WOCKPHARMAWockhardt | ₹1,889.60 | +0.46% | +38.2% | ₹30,705 Cr | 144.8 | — |
| SAILIFESai Life Sciences | ₹1,396.80 | −0.06% | +63.2% | ₹29,652 Cr | 85.1 | — |
| KIMSKrishna Institute of Medical Sciences | ₹671.30 | +0.04% | −5.5% | ₹28,195 Cr | 111.9 | — |
| PPLPHARMAPiramal Pharma | ₹194.27 | +1.97% | +1.2% | ₹25,864 Cr | — | — |
| NEULANDLABNeuland Laboratories | ₹18,855.00 | −0.45% | +16.3% | ₹24,191 Cr | 66.3 | — |
Ask anything about Krishna Institute of Medical Sciences
Pivot answers on the live chart with evidence you can check, and tests strategies against KIMS's own history. Try: “Why has KIMS moved over the last three months?” · “Backtest a 50-day moving-average crossover on KIMS over five years” · “Compare KIMS with MEDANTA on margins and valuation”
Frequently asked questions about Krishna Institute of Medical Sciences
What is the share price of Krishna Institute of Medical Sciences today?
Krishna Institute of Medical Sciences (NSE: KIMS) last closed at ₹671.30 on 22 Oct 2026. Its 52-week high is ₹858.00 and its 52-week low is ₹575.80.
What is the market cap of Krishna Institute of Medical Sciences?
Krishna Institute of Medical Sciences' market capitalisation is ₹28,195 Cr (₹28,195 Cr) at the 22 Oct 2026 close, ranking 286th among the NSE companies Pivot tracks.
What is the P/E ratio of Krishna Institute of Medical Sciences?
Krishna Institute of Medical Sciences trades at a trailing P/E of 111.9. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 66.3.
What is the ROE and ROCE of Krishna Institute of Medical Sciences?
Return on equity was 18.0% in FY25 and return on capital employed was 13.0% in FY25 (consolidated figures).
Is Krishna Institute of Medical Sciences a debt-free company?
No. Krishna Institute of Medical Sciences' debt-to-equity ratio was 0.89 in FY25, with total debt of ₹1,654 Cr.
What were Krishna Institute of Medical Sciences' latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Krishna Institute of Medical Sciences reported revenue of ₹1,180 Cr, +35.3% year on year, and net profit of ₹36 Cr, −57.2% year on year.
How has Krishna Institute of Medical Sciences stock performed over the last year?
Krishna Institute of Medical Sciences' share price has fallen 5.5% over the past year, −14.8% over three months and −15.0% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Krishna Institute of Medical Sciences?
As of 30 Jun 2026: promoters 32.50%, foreign institutions 14.74%, domestic institutions 34.43%, non-institutions 18.33%. 10.26% of promoter shares were pledged.
Who are Krishna Institute of Medical Sciences' competitors?
The listed Pharma & Healthcare companies closest to Krishna Institute of Medical Sciences by market cap are Global Health, Dr. Lal Path Labs, Wockhardt, Sai Life Sciences, Piramal Pharma and Neuland Laboratories.
Is Krishna Institute of Medical Sciences a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Krishna Institute of Medical Sciences' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on KIMS against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with K · all NSE stocks · this page as text